Targeting RAS driven tumour immune evasion

Informazioni relative al progetto

RASImmune

ID dell’accordo di sovvenzione: 834692

DOI

10.3030/834692

Data della firma CE 7 Giugno 2019

Data di avvio 1 Agosto 2019

Data di completamento 31 Gennaio 2026

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale

€ 2 500 000,00

Contributo UE

€ 2 500 000,00

Coordinato da

THE FRANCIS CRICK INSTITUTE LIMITED
United Kingdom

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Pubblicazioni

Peer reviewed articles (12)

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

Autori: J. Boumelha, S. de Carné Trécesson, E.K. Law, P. Romero-Clavijo, M.A. Coelho, K. Ng, E. Mugarza, C. Moore, S. Rana, D.R. Caswell, M. Murillo, D.C. Hancock, P.P. Argyris, W.L. Brown, C. Durfee, L.K. Larson, R.I. Vogel, A. Suárez-Bonnet, S.L. Priestnall, P. East, S.J. Ross, G. Kassiotis, M. Molina-Arcas, C. Swanton, R. Harris, J. Downward
Pubblicato in: Cancer Research, 2022, ISSN 1538-7445
Editore: AACR
DOI: 10.1158/0008-5472.can-22-0325

Combined targeting of G protein‐coupled receptor and EGF receptor signaling overcomes resistance to PI 3K pathway inhibitors in PTEN ‐null triple negative breast cancer

Autori: Davide Zecchin, Christopher Moore, Fanourios Michailidis, Stuart Horswell, Sareena Rana, Michael Howell, Julian Downward
Pubblicato in: EMBO Molecular Medicine, Numero 12/8, 2020, ISSN 1757-4676
Editore: John Wiley & Sons Ltd.
DOI: 10.15252/emmm.202011987

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry

Autori: van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Kelly G, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J
Pubblicato in: Nature Communications, 2021, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1038/s41467-021-26214-x

Stratification method based on oncogenic RAS pathway activity predicts outcome in lung adenocarcinoma

Autori: P. East, G.P. Kelly, D. Biswas, M. Marani, D.C. Hancock, C. Swanton, J. Downward, S. de Carné Trécesson
Pubblicato in: Nature Communications, 2022, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1038/s41467-022-33290-0

Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets

Autori: Rachel Cooley, Neesha Kara, Ning Sze Hui, Jonathan Tart, Chloë Roustan, Roger George, David C. Hancock, Brock F. Binkowski, Keith V. Wood, Mohamed Ismail, Julian Downward
Pubblicato in: Wellcome Open Research, Numero 5, 2020, Pagina/e 20, ISSN 2398-502X
Editore: Wellcome Trust
DOI: 10.12688/wellcomeopenres.15675.2

Immunotherapy boosts protective antibody responses against endogenous retroviruses in lung adenocarcinoma

Autori: K.W. Ng, J. Boumelha, K.S.S. Enfield, J. Almagro, H. Cha, O. Pich, T. Karasaki, D.A. Moore, R. Salgado, M. Sivakumar, G. Young, M. Molina-Arcas, S. de Carné Trécesson, P. Anastasiou, A. Fendler, L. Au, S.T.C. Shepherd, C. Martínez-Ruiz, C. Puttick, J.R.M. Black, T.B.K. Watkins, H. Kim, S. Shim, N. Faulkner, J. Attig, S. Veeriah, N. Magno, S. Ward, A.M. Frankell, M. Al Bakir, E.L. Lim, M.S. Hill
Pubblicato in: Nature, 2023, ISSN 1476-4687
Editore: Nature Publishing Group
DOI: 10.1038/s41586-023-05771-9

Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110alpha

Autori: M. Ismail, S.R. Martin, R. George, F. Houghton, G. Kelly, R.A.G. Chaleil, P. Anastasiou, X. Wang, N. O’Reilly, S. Federico, D. Joshi, H. Nagaraj, R. Cooley, N.S. Hui, M. Molina-Arcas, D.C. Hancock, A. Tavassoli, J. Downward
Pubblicato in: Scientific Reports, 2023, ISSN 2045-2322
Editore: Nature Publishing Group
DOI: 10.1038/s41598-023-28756-0

Micro-CT image acquisition, processing, and segmentation to track lung cancer progression and characterise pulmonary nodules in mice

Autori: M.Z. Thin, C. Moore, T. Snoeks, T. Kalber, J. Downward, A. Behrens
Pubblicato in: Nature Protocols, 2022, ISSN 1750-2799
Editore: Nature Publishing Group
DOI: 10.1038/s41596-022-00769-5

Lung adenocarcinoma promotion by air pollutants

Autori: W. Hill, E.L. Lim, C.E. Weeden, C. Lee, M. Augustine, K. Chen, F-C. Kuan, F. Marongiu, E.J. Evans Jr, D.A. Moore, F.S. Rodrigues, O. Pich, B. Bakker, H. Cha, R. Myers, F. van Maldegem, J. Boumelha, S. Veeriah, A. Rowan, C. Naceur-Lombardelli, T. Karasaki, M. Sivakumar, S. De, D.R. Caswell, A. Nagano, J.R.M. Black, C. Martínez-Ruiz, M.H. Ryu, R.D. Huff, S. Li, M-J. Favé, A. Magness, A. Suárez-Bo
Pubblicato in: Nature, 2023, ISSN 1476-4687
Editore: Nature Publishing Group
DOI: 10.1038/s41586-023-05874-3

Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

Autori: E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. Llorian Sopena, P. East, R. Ambler, P. Anastasiou, P. Romero Clavijo, K. Valand, M. Cole, M. Molina-Arcas, J. Downward
Pubblicato in: Science Advances, 2022, ISSN 2375-2548
Editore: AAAS
DOI: 10.1126/sciadv.abm8780

Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasis

Autori: G. Tomić, C. Sheridan, A. Refermat, M. Baggelaar, J. Sipthorp, B. Sudarshan, C.A. Ocasio, A. Suarez-Bonnet, S. Priestnall, E. Herbert, E. Tate, J. Downward
Pubblicato in: Cell Reports, 2024, ISSN 2211-1247
Editore: Cell Press
DOI: 10.1016/j.celrep.2024.114224

In vivo CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer

Autori: J. Boumelha, A. de Castro, N. Bah, H. Cha, S. de Carné Trécesson, S. Rana, P. Anastasiou, E. Mugarza, C. Moore, R. Goldstone, P. East, K. Litchfield, S-H. Lee, M. Molina-Arcas, J. Downward
Pubblicato in: Cancer Research, 2024, ISSN 1538-7445
Editore: AACR
DOI: 10.1158/0008-5472.can-23-2627

Other (2)

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

Autori: Panayiotis Anastasiou, Chris Moore, Sareena Rana, Andrea de Castro, Mona Tomaschko, Jesse Boumelha, Edurne Mugarza, Cristina Blaj, Sophie de Carné, Robert Goldstone, Jacqueline A.M. Smith, Elsa Quintana, Miriam Molina-Arcas, Julian Downward
Pubblicato in: 2024
Editore: Cold Spring Harbor Press
DOI: 10.1101/2024.01.15.575765

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

Autori: Megan Cole, Panayiotis Anastasiou, Claudia Lee, Chris Moore, Edurne Mugarza, Martin Jones, Karishma Valand, Sareena Rana, Emma Colliver, Mihaela Angelova, Katey S.S. Enfield, Alastair Magness, Asher Mullokandov, Gavin Kelly, Tanja D. de Gruijl, Miriam Molina-Arcas, Charles Swanton, View ORCID ProfileJulian Downward, Febe van Maldegem
Pubblicato in: 2024
Editore: Cold Spring Harbor Press
DOI: 10.1101/2024.04.11.588725